The Europe asthma treatment market is projected to grow from USD 7.36 billion in 2025 to approximately USD 11.54 billion by 2035, registering a CAGR of 4.60%, driven by rising respiratory disorders, improved diagnostics, and advancements in targeted therapies.

Europe Asthma Treatment Market Statical Scope

Alongside combination therapies, low-carbon inhalers and sustainable innovations are major trends throughout Europe. Results are improving with a focus on early diagnosis, preventive care, and standardized treatment protocols. Product innovation is being stimulated by regulatory support for eco-friendly devices.

The market is fueled by increased use of combination treatments, growing awareness, and advantageous reimbursement policies. Treatment penetration is being improved by early diagnosis initiatives and robust regulatory support for respiratory care . Furthermore, the market is expanding due to the increased focus on sustainable inhaler devices and preventive healthcare.

Europe Asthma Treatment Market Share, By Drug Class, 2025 (%)

• Anti-inflammatory- Anti-inflammatory drugs lead the market with a 40% share driven by strong clinical guidelines promoting preventive care.
• Bronchodilators- Bronchodilators account for a significant portion, with 34% of the market share driven by the continued need for immediate symptom relief.
• Combination Therapy- Combination therapy holds a notable segment, 26%, of the market driven by rising adoption of advanced treatment protocols.

Europe Asthma Treatment Market Share, By Product, 2025 (%)

• Inhalers- Inhalers dominate the market with 84% share driven by high patient compliance and advanced inhaler technologies.
• Nebulizers- Nebulizers account for a smaller but significant portion, with 16% of the market share driven by usage in elderly and critical care patients.

Europe Asthma Treatment Market Share, By Route of Administration, 2025 (%)

• Oral- Oral therapies account for a notable share, representing 20% of the market driven by ease of administration in chronic treatment plans.
• Inhaled- Inhaled therapies led the market with 74% of the market share, driven by superior efficacy and widespread clinical preference.

Top Companies in the Europe Asthma Treatment Market

• Teva Pharmaceutical Industries Ltd.
• GSK plc
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Sanofi.
• Koninklijke Philips N.V.
• BD
• Covis Pharma

Segments Covered in the Report

By Drug Class

• Anti- inflammatory
• Bronchodilators
• Combination Therapy

By Product

• Inhalers
• Nebulizers

By Route of Administration

• Oral
• Inhaled
• Others